Senolytic and anti-fibrotic agents tested to enhance stem cell therapy for knee osteoarthritis in RCT
This prospective, randomized, double-blind, active-control trial evaluated whether a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, could improve the effect of autologous bone marrow aspirate concentrate (BMAC) injection into osteoarthritic knees. The abstract provided reports the trial design and intervention structure but does not report results, efficacy outcomes, or safety findings.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 16, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with osteoarthritis of the knee
- Primary outcome
- Safety and efficacy of senolytic and anti-fibrotic agents in improving the beneficial effect of BMAC for osteoarthritis
- Effect size
- —
- Significance
- Not reported
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Sources
Primary source
- Steadman Philippon Research Institute ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.